EU-Solidact

Full Title: EU SolidAct: An Adaptive Pandemic and Emerging Infection Platform Trial (Bari-SolidAct)

Details: EU SolidAct is a randomized, multifactorial, adaptive platform trial for COVID-19 and emerging infectious diseases and pandemics. The purpose of this study is to evaluate the effect of a range of interventions to improve outcome of patients admitted to hospital with COVID-19

Specialty: Infectious Disease

Principal Investigator: Prof. John Laffey

Study Status: Paused to recruitment

Identifier: NCT04891133